01/06/2025 Ardelyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference
11/20/2024 Ardelyx to Participate at the Piper Sandler 36th Annual Healthcare Conference
11/08/2024 Ardelyx Responds to District Court Decision Granting Motion to Dismiss
11/05/2024 Ardelyx to Participate at the 2024 Jefferies London Healthcare Conference
10/31/2024 Ardelyx Reports Third Quarter 2024 Financial Results and Provides Business Update
10/28/2024 Ardelyx Presents Results from its IBS in America 2024 Supplemental Survey at the American College of Gastroenterology’s (ACG) Annual Meeting
10/24/2024 Ardelyx Shares Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) at the American Society of Nephrology’s Kidney Week
10/22/2024 Ardelyx Announces Launch of Gut Matters: Discoveries and Innovations, a New Podcast for the IBS-C Patient Community
10/21/2024 Ardelyx Announces the Derek Forfang Patient Advocate Award to Recognize Advocates for the Chronic Kidney Disease Community
10/17/2024 Ardelyx to Report Third Quarter 2024 Financial Results on October 31, 2024
10/15/2024 Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the American Society of Nephrology’s Kidney Week
10/09/2024 Ardelyx Announces Publication of a Review Article Exploring the Patient Burden and Therapeutic Landscape of IBS-C in the U.S. in Clinical and Experimental Gastroenterology
09/05/2024 Ardelyx to Participate at the 2024 Cantor Global Healthcare Conference
08/08/2024 Ardelyx Appoints Experienced Biopharma Executive, Eric Foster, as Chief Commercial Officer
08/01/2024 Ardelyx Reports Second Quarter 2024 Financial Results and Provides Business Update
07/31/2024 Ardelyx Announces Publication of Two Plain Language Summaries from XPHOZAH® (tenapanor) Clinical Trials in Current Medical Research and Opinion
07/18/2024 Ardelyx to Report Second Quarter 2024 Financial Results on August 1, 2024
07/17/2024 Ardelyx, AAKP and NMQF File Lawsuit to Protect Dialysis Patient Choice and Timely Access to Clinically Meaningful Medicines
07/02/2024 To Preserve Patient Access to XPHOZAH®, Ardelyx Chooses Not to File for TDAPA
06/28/2024 Ardelyx Presents Additional Data Detailing Educational Needs Related to IBS-C Management Across Healthcare Disciplines
05/30/2024 Ardelyx, Inc. Reports Employment Inducement Grants
05/22/2024 Ardelyx to Participate at the 2024 Jefferies Global Healthcare Conference
05/21/2024 Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults
05/16/2024 Ardelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor)
05/14/2024 Ardelyx, Inc. Reports Employment Inducement Grants
05/07/2024 Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference
05/02/2024 Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update
05/01/2024 Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the National Kidney Foundation 2024 Spring Clinical Meetings
04/18/2024 Ardelyx to Report First Quarter 2024 Financial Results on May 2, 2024
03/28/2024 Ardelyx, Inc. Reports Employment Inducement Grants
03/25/2024 Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and Strategy
03/12/2024 Ardelyx, Inc. Reports Employment Inducement Grants
02/27/2024 Ardelyx to Participate at the Cowen 44th Annual Health Care Conference
02/22/2024 Ardelyx Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
02/01/2024 Ardelyx to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
01/12/2024 Ardelyx, Inc. Reports Employment Inducement Grants
01/08/2024 Ardelyx Provides Update on Growing Commercial Momentum and 2024 Strategic Priorities
01/03/2024 Ardelyx to Provide Company Update on IBSRELA® and Host a KOL Discussion on the IBS-C Landscape on Monday, January 8
12/20/2023 Ardelyx, Inc. Reports Employment Inducement Grants
11/21/2023 Ardelyx, Inc. Reports Employment Inducement Grants
11/21/2023 Ardelyx to Participate at the Piper Sandler 35th Annual Healthcare Conference
11/15/2023 XPHOZAH® (tenapanor) Granted Orphan Drug Designation by U.S. FDA for the Treatment of Pediatric Hyperphosphatemia
11/13/2023 Ardelyx Announces Departure of Board Member
11/10/2023 Ardelyx to Participate at the Jefferies London Healthcare Conference
11/06/2023 Ardelyx Announces XPHOZAH® (tenapanor) Now Available in the United States
11/03/2023 Ardelyx Shares Positive Data from Studies of XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor, at ASN Kidney Week 2023
10/31/2023 Ardelyx Reports Third Quarter 2023 Financial Results and Updates 2023 U.S. IBSRELA® Net Sales Revenue Guidance
10/30/2023 Ardelyx, Inc. Reports Employment Inducement Grants
10/23/2023 Ardelyx Shares Positive Data on Symptom Response During Treatment With IBSRELA® (tenapanor) for IBS-C and hosts IBS-C Product Theater at ACG 2023
10/18/2023 Ardelyx to Report Third Quarter 2023 Financial Results on October 31, 2023
10/17/2023 Ardelyx Announces Amendment of Debt Financing Agreement with SLR Capital Partners to Provide $50 Million of Additional Committed Capital
10/17/2023 FDA Approves XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor
10/13/2023 Ardelyx to Present Data Updates for XPHOZAH (tenapanor) for Hyperphosphatemia at Kidney Week 2023 November 1-5 in Philadelphia, PA
10/04/2023 Ardelyx Shares Preliminary Data on Use of IBSRELA® (tenapanor) in Pediatric IBS-C Patients at NASPGHAN 2023
09/28/2023 Ardelyx Announces Publication of Positive Results from T3MPO-3 Long-Term Open-Label Safety Trial of Tenapanor for IBS-C in the Journal of Neurogastroenterology and Motility
09/25/2023 Tenapanor for Hyperphosphatemia Approved in Japan
09/11/2023 Ardelyx Showcased Encouraging Data on Treatment Satisfaction and Efficacy of IBSRELA® (tenapanor) for IBS-C at GHAPP 2023
09/08/2023 Ardelyx to Present at the H.C. Wainwright 25th Annual Global Investment Conference
09/07/2023 Ardelyx, Inc. Reports Employment Inducement Grants
08/02/2023 Ardelyx Reports Second Quarter 2023 Financial Results and Provides 2023 IBSRELA Net Sales Revenue Guidance
07/27/2023 Ardelyx, Inc. Reports Employment Inducement Grants
07/26/2023 Ardelyx to Report Second Quarter 2023 Financial Results on August 2, 2023
07/20/2023 Ardelyx to Present at the H.C. Wainwright 2nd Annual Kidney Conference
07/13/2023 Ardelyx Announces Acceptance of New Drug Application for Tenapanor for Hyperphosphatemia in China
06/29/2023 Ardelyx, Inc. Reports Employment Inducement Grants
06/05/2023 Leading Proxy Advisory Firms ISS and Glass Lewis Recommend Ardelyx Stockholders Vote in Favor of Proposed Share Increase
05/31/2023 Ardelyx to Present at the Jefferies 2023 Healthcare Conference
05/23/2023 Ardelyx, Inc. Reports Employment Inducement Grants
05/17/2023 Ardelyx Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH® (tenapanor)
05/15/2023 Ardelyx, Inc. Reports Employment Inducement Grants
05/09/2023 Ardelyx Presents Positive Data at DDW 2023 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults
05/03/2023 Ardelyx Reports First Quarter 2023 Financial Results and Provides Business Update
05/01/2023 Ardelyx Announces Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week Conference
04/26/2023 Ardelyx to Report First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023
04/18/2023 Ardelyx Resubmits New Drug Application to U.S. Food and Drug Administration for XPHOZAH® (tenapanor)
04/13/2023 Ardelyx, Inc. Reports Employment Inducement Grants
04/12/2023 Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2023 Spring Clinical Meetings
03/02/2023 Ardelyx Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
02/28/2023 Ardelyx Publishes First Environmental, Social and Governance (ESG) Report
02/27/2023 Ardelyx to Participate at the Cowen 43rd Annual Health Care Conference
02/23/2023 Ardelyx to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 2, 2023
02/02/2023 Ardelyx, Inc. Reports Employment Inducement Grants
12/29/2022 FDA Grants Appeal for Ardelyx's XPHOZAH® (tenapanor)
12/23/2022 Ardelyx, Inc. Reports Employment Inducement Grants
12/16/2022 Ardelyx Provides Update on FDA Appeal for XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis
11/22/2022 Ardelyx to Present at the 34th Annual Piper Sandler Healthcare Conference
11/16/2022 Ardelyx Announces FDA Advisory Committee Votes that the Benefits of XPHOZAH® (tenapanor) Outweigh its Risks for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis
11/16/2022 Ardelyx Stock Trading Halted Today; FDA Advisory Committee to Discuss XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis
11/04/2022 National Kidney Foundation and Ardelyx, Inc. Survey Finds Dialysis Patients Struggle to Maintain Serum Phosphorus Levels
11/03/2022 Ardelyx Reports Third Quarter 2022 Financial Results and Recent Business Highlights
11/03/2022 Ardelyx Presents New Data Analyses at Kidney Week 2022, Further Supporting the Clinical Relevance of XPHOZAH® (tenapanor), an Investigational, Phosphate Absorption Inhibitor to Control Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dial
11/02/2022 Ardelyx, Inc. Reports Employment Inducement Grants
10/31/2022 Ardelyx Collaboration Partner, Kyowa Kirin, Announces Submission of New Drug Application for Tenapanor for Hyperphosphatemia in Japan
10/27/2022 Ardelyx to Report Third Quarter 2022 Financial Results on November 3, 2022
10/24/2022 Ardelyx to Present Poster Presentations on IBSRELA® (tenapanor) for Adult Patients with IBS-C at the American College of Gastroenterology 2022 Annual Scientific Meeting
10/20/2022 Ardelyx Announces Poster Presentations on XPHOZAH® (tenapanor) at ASN's Kidney Week 2022
09/30/2022 Ardelyx, Inc. Reports Employment Inducement Grants
09/06/2022 Ardelyx to Participate in Upcoming Investor Conferences
08/04/2022 Ardelyx Reports Second Quarter 2022 Financial Results and Recent Business Highlights
08/02/2022 Ardelyx to Present at the 2022 Wedbush PacGrow Healthcare Conference
